ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF RAMIPRIL AND TELMISARTAN IN PHARMACEUTICAL DOSAGE FORM BY USING RP-HPLC METHOD
A simple and reliable reverse phase high-performance liquid chromatography method was developed and validated for analysis of Ramipril and Telmisartan in pure and pharmaceutical dosage form. The method was developed on symmetric C18 (4.6 x 150mm, 5ïm, Make: Zorbax), with a mobile phase of phosphate buffer (PH 3.0): Acetonitrile (55:45) %v/v. The effluent was monitored by Waters HPLC model containing Alliance 2695 with 2487 detector, variable wavelength prominence UV/ VIS detector SPD-20A (VP series). Calibration curve was linear over the concentration range of 1.25-6.25μg/ml for Ramipril and 10-50μg/ml for Telmisartan. Recovery of Ramipril and Telmisartan was found to be in the range of 99.1 -100.2%.The limit of detection (LOD) and quantification (LOQ) were 2.97 and 9.84 for Ramipril and 3.0 and 9.95 for Telmisartan, respectively. The retention time and run time was very short; hence it is cost effective, making it more economical and rapid. Hence, this method can be used for the analysis of large number of samples.